Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Filings indexed 984 across all filing types
Latest filing 2021-07-07 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-07-07 English
FORM 4
Director's Dealing
2021-07-06 English
FORM 4
Director's Dealing
2021-07-06 English
FORM 3
Director's Dealing
2021-07-06 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-07-06 English
8-K/A
Regulatory Filings
2021-07-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.